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Background: We investigated the role of the renin-angiotensin system (RAS) in women with signs and symptoms of ischemia without obstructive 
coronary artery disease (CAD). Microvascular dysfunction has been suggested to explain this syndrome, but the mechanisms and treatments are 
unclear.
Methods: In an ancillary study of the WISE, 78 women with microvascular dysfunction, defined as coronary flow reserve [CFR] following adenosine 
<3.0, and no obstructive CAD were randomized to either angiotensin-converting enzyme inhibition (ACE-I) with quinapril or placebo for 16 weeks. The 
primary response variable was CFR after 16 weeks, and the secondary response variable was freedom from angina assessed from the Seattle Angina 
Questionnaire.
Results: For the primary outcome, an ACE-I treatment effect was observed (multivariate, p = 0.02). The CFR at baseline (p = 0.0007), history of 
diabetes (p = 0.02), and study site (p=0.03, p=0.003) also contributed independently to the primary outcome. For the secondary outcome: ACE-I 
treatment (p = 0.037) and CFR response at 16 weeks (p = 0.008) contributed to symptom response, as did baseline angina frequency (p <0.0001) 
and treatment duration (4, 8, 12, or 16 weeks; p = 0.016). The benefit of ACE-I was more pronounced in women with baseline CFR ≤ 2.5 than in 
women with baseline CFR 2.5-3.0 (p = 0.03 for the interaction).
Conclusions: Microvascular dysfunction, in women with signs and symptoms of ischemia who lack obstructive CAD, improves with ACE-I and is 
linked with reduction in angina. This beneficial response is most pronounced among women with lower baseline CFR values, suggesting that the RAS 
may be most involved among women with the most severe microvascular defect.
